Project Grant R01FD006325

This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $703,540.00 to Brigham & Women's Hospital Inc. to develop and optimize highly effective treatments for head and neck cancer using in situ implantable microdevices. The primary goals are to: Conduct a clinical study to validate the performance of the microdevice in predicting patients' clinical response to immunotherapy and chemotherapy for head and neck squamous cell...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to support the development and commercialization of a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to create a small peptide-based fluorescent probe that can specifically stain HNC tumors to assist surgeons in identifying tumors...

The U.S. Food and Drug Administration (FDA) awarded a $650,000 Project Grant under the FDA Research program (CFDA 93.103) to Targeted Therapy Technologies, LLC in Irvine, CA. The grant will support a Phase II expanded access clinical trial for a novel topotecan chemoplaque treatment for retinoblastoma, a rare childhood eye cancer. The chemoplaque technology aims to deliver sustained, localized topotecan treatment to the eye while minimizing systemic exposure, providing an alternative to...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a Phase I clinical trial to evaluate the safety and efficacy of CSPG4-targeted CAR-T cell therapy in adult patients with head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum and PD-1 inhibitor treatment. The award of $627,456 will fund the single-center, open-label clinical trial over a 5-year period from December 2024 to November 2029....

The National Institute of Dental and Craniofacial Research (NIDCR) awarded Keraceuticals, Inc. a $799,270 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to develop a novel class of anticancer drugs called 1,3-thioureas for the treatment of oral squamous cell carcinoma (OSCC). The funding will support formulating the lead compound CIDD99 for oral and/or intravenous administration, confirming its efficacy in mouse OSCC models, and evaluating its combination with...

This Project Grant award of $466,500.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop near-infrared chemiluminescent and fluorescent (NIR CFL) chitosan-based nanoparticles (CNPs) to improve the detection of micrometastatic cancer and guide image-guided surgery. The nanoparticles can be activated by body heat and stored at low temperatures for convenience and safety. The research...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $677,176 to The Research Foundation For The State University Of New York to develop an interstitial chemophototherapy (I-CPT) intervention for locally advanced pancreatic cancer. The goal is to translate a novel liposomal irinotecan formulation with porphyrin-phospholipid into a clinically relevant tumor ablation paradigm using image-guided placement of...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University to develop a novel immunotherapy approach for treating HPV-associated head and neck cancers. The key products and services to be delivered under this award include: 1) Evaluating the ability of Salmonella-derived nanoparticles coated with the HPV E7 antigen (SOMV-9RE7) to induce...

This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...